<DOC>
	<DOCNO>NCT01738477</DOCNO>
	<brief_summary>The purpose follow-up study evaluate persistence antibody vaccine antigens 10 year booster vaccination either Tdap Td , also assess immunogenicity safety another dose Boostrix , administer study . This protocol post deal objectives outcome measure extension phase . The objective outcome measure primary phase present separate protocol posting ( NCT number = NCT00109330 ) .</brief_summary>
	<brief_title>Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Boostrix™ Vaccine Previously Boosted Young Adults</brief_title>
	<detailed_description>Subjects previously vaccinate either Boostrix control Td vaccine study NCT00109330 . Only subject part primary study invite participate study . All subject receive single dose Boostrix Visit 1 ( Day 0 ) subject observe till Visit 2 ( Day 30 ) safety term solicit adverse event ( 4 day post vaccination ) , unsolicited adverse event ( 31 day post vaccination ) serious adverse event ( trial period ) . A blood sample collect subject vaccination ( Visit 1 ) one month vaccination ( Visit 2 ) antibody estimation . This summary update follow Protocol amendment 2 date 03 October 2013 . The protocol amend facilitate enrolment : - - Extending window period re-vaccination ± 6 month ± 300 day Year 10 time point . - - Extending recruitment period 6 month 14 month . The format non-inferiority criterion first co-primary objective update keep align format non-inferiority criterion second co-primary objective .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol ( e.g . completion diary card , return followup visit ) . Subjects receive dose Tdap Td vaccines 10 year ( +/300 day ) back , study NCT00109330 . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 1 month completion vaccine dose . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior booster vaccine dose . For corticosteroid , mean prednisone ( ≥ 20 mg/day ( adult subject ) , equivalent . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol period start 30 day end 31 day dose vaccine , exception Influenza vaccine allow throughout study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Previous vaccination diphtheria , tetanus pertussis since last dose receive Study NCT00109330 . History diphtheria , tetanus pertussis disease follow receipt booster dose Study NCT00109330 . Severe allergic reaction ( e.g . anaphylaxis ) previous administration tetanus toxoid , diphtheria toxoid , pertussisantigen contain vaccine , component Boostrix . Hypersensitivity latex . Encephalopathy ( e.g . coma , decrease level consciousness , prolonged seizure ) unknown etiology occur within 7 day follow previous vaccination pertussiscontaining vaccine . History neurological disorder seizure . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Acute disease and/or fever time enrolment . Fever define temperature ≥ 99.5°F oral , axillary tympanic route , ≥ 100.4°F rectal route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede booster dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution 1 month postvaccination .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Booster</keyword>
	<keyword>Tdap</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Repeat dose</keyword>
	<keyword>Safety</keyword>
	<keyword>BoostrixTM</keyword>
	<keyword>Persistence</keyword>
</DOC>